Khavinson Bioregulators: Complete Guide to Cytomax Peptides

EXOMA Scientific Team · Publicado el 13 de abril de 2026 · Actualizado el 26 de julio de 2026

Discover the bioregulator peptides developed by Prof. Vladimir Khavinson. Scientific guide on Bronchogen, Cardiogen, Cortagen, Vesugen, and more Cytomax peptides.

What are Khavinson's Bioregulators?

Peptide bioregulators, developed by the Prof. Vladimir Khavinson of the Institute of Bioregulation and Gerontology in Saint Petersburg, represent a unique class of short peptides (2-4 amino acids) designed to interact with specific DNA sequences and modulate tissue gene expression.

Unlike conventional peptides that act on membrane receptors, Citomax bioregulators penetrate the cell nucleus and bind to promoter regions of DNA, activating genes specific to the target tissue.

Molecular Mechanism of Action

The fundamental mechanism of bioregulators is based on the epigenetic regulation:

1. Nuclear penetration: Short peptides cross the cell and nuclear membrane without the need for receptors
2. DNA binding: Se unen a secuencias específicas en regiones promotoras de genes
3. Transcriptional modulation: Activan o normalizan la transcripción de proteínas específicas del tejido
4. Functional restoration: The tissue recovers its optimal protein synthesis capacity

This mechanism was validated in more than 40 years of research with clinical studies that included more than 15 million patients in Russia.

Main Bioregulators and their Target Tissues

Bronchogen (Ala-Asp-Glu)

Bronchogen is a tripeptide designed for the bronchopulmonary tissue. Its mechanism includes:

• Modulation of pulmonary surfactant expression
• Regulation of the bronchial inflammatory response
• Normalization of mucociliary function
• Support for regeneration of the respiratory epithelium

Preclinical studies have demonstrated its ability to normalize the levels of proinflammatory cytokines (IL-6, TNF-α) in models of lung injury.

Cardiogen (Ala-Glu-Asp)

Cardiogen acts specifically on the myocardial tissue:

• Regulation of the expression of cardiac contractile proteins
• Modulation of myocardial ion channels
• Support for the energy metabolism of the cardiomyocyte
• Normalization of the cellular depolarization rhythm

Research suggests cardioprotective effects through modulation of the Nrf2/ARE antioxidant response pathway.

Cortagen (Ala-Glu-Asp-Pro)

Cortagen is a tetrapeptide directed at the central nervous system:

• Modulation of the expression of neurotrophic factors (BDNF, NGF)
• Regulation of glutamatergic and GABAergic neurotransmission
• Support of synaptic plasticity
• Protection against neuronal oxidative stress

Vesugen (Lys-Glu-Asp)

Vesugen focuses on the vascular system:

• Regulation of endothelial nitric oxide synthase (eNOS) expression
• Modulation of endothelial function
• Normalization of vascular permeability
• Support of physiological angiogenesis

Other Important Bioregulators

Scientific Evidence

The scientific basis of the bioregulators includes:

• More than 200 publications in indexed journals
• Clinical studies at the Institute of Bioregulation and Gerontology
• Longevity research that demonstrated a 28% reduction in mortality in a 15-year study with geriatric patients
• International patents for specific peptide sequences

Kiev Study (2003)

One of the most cited studies involved 266 patients over 60 years of age treated with a combination of Epithalamin (pineal) and Thymalin (thymus) for 6 years. The results showed:

• Significant reduction in cardiovascular mortality
• Improvement in immune function markers
• Normalization of circadian melatonin rhythms

Advantages of Short Peptides

The Khavinson bioregulators present unique pharmacological advantages:

• High oral bioavailability: Being di- and tripeptides, they resist gastric degradation
• No side effects reported in more than 40 years of clinical research
• They do not produce tolerance: By acting at the gene level, they do not desensitize receptors
• Cumulative effect: The changes in gene expression persist weeks after treatment
• Tissue specificity: Each peptide acts exclusively on its target tissue

Research Protocols

In the research context, bioregulators are typically studied in:

• Cycles of 10-30 days with rest periods
• Synergistic combinations (e.g. Cortagen + Vesugen for vascular neuroprotection)
• Standardized doses based on the protocols of the Saint Petersburg Institute

Conclusion

The Khavinson bioregulators represent a unique paradigm in peptide pharmacology. Their mechanism of epigenetic regulation, combined with decades of clinical research, positions them as compounds of high interest for research in longevity and regenerative medicine.

At Exoma Peptides we offer the complete line of Citomax bioregulators with certified purity and COA included in every product.

References

Material for research use only. Verified primary sources supporting the scientific claims of this article:

1. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. doi:10.1023/A:1025493705728. PMID 12937682. (in vitro / células humanas)
2. Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506. PMID 15455129. (in vitro / células humanas)
3. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. doi:10.1134/S0006297911110022. PMID 22117547. (in vitro)
4. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. doi:10.1007/s10522-009-9249-8. PMID 19830585. (revisión)
5. Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. doi:10.1007/s10517-011-1332-x. PMID 22451889. (human / clinical follow-up)